SRT 2104

• CAT Number: I000394
• CAS Number: 1093403-33-8
• Molecular Formula: C26H24N6O2S2
• Molecular Weight: 516.64
• Purity: ≥95%
• Target: Sirtuin
• Solubility: DMSO: ＜ 6 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
• InChIKey: LAMQVIQMVKWXOC-UHFFFAOYSA-N
• SMILES: O=C(C1=C(C)N=C(C2=CC=CN=C2)S1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCOCC6)=N4

SRT2104 (CAT: I000394) is a small molecule activator of the enzyme SIRT1 (sirtuin 1), a member of the sirtuin family of proteins involved in various cellular processes, including aging, metabolism, and stress response. SRT2104 acts by increasing the deacetylase activity of SIRT1, which in turn influences multiple downstream targets. Through its activation of SIRT1, SRT2104 has been proposed to have potential benefits in improving metabolic health, enhancing mitochondrial function, and extending lifespan in various preclinical studies.

Reference

[1]. Jiang WJ. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun. 2008 Aug 29;373(3):341-4.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases such as type 2 diabetes. SIRT1, an NAD(+)-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produces beneficial effects on glucose homeostasis and insulin sensitivity. Activation of SIRT1 leads to enhanced activity of multiple proteins, including peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) and FOXO which helps to mediate some of the in vitro and in vivo effects of sirtuins. Resveratrol, a polyphenolic SIRT1 activator, mimics the effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance. In this review, we summarize recent research advances in unveiling the molecular mechanisms that underpin sirtuin as therapeutic candidates and discuss the possibility of using resveratrol as potential drug for treatment of diabetes.